Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF.
Journal
Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
05
07
2020
accepted:
12
11
2020
pubmed:
24
12
2020
medline:
21
8
2021
entrez:
23
12
2020
Statut:
ppublish
Résumé
The sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. This report explores the effect of dapagliflozin on incident type 2 diabetes (T2D) in the cohort without diabetes enrolled in the trial. The subgroup of 2,605 patients with heart failure and reduced ejection fraction (HFrEF), no prior history of diabetes, and an HbA At baseline, the mean HbA In this exploratory analysis among patients with HFrEF, treatment with dapagliflozin reduced the incidence of new diabetes. This potential benefit needs confirmation in trials of longer duration and in people without heart failure.
Identifiants
pubmed: 33355302
pii: dc20-1675
doi: 10.2337/dc20-1675
doi:
Substances chimiques
Benzhydryl Compounds
0
Glucosides
0
dapagliflozin
1ULL0QJ8UC
Banques de données
figshare
['10.2337/figshare.13235543']
ClinicalTrials.gov
['NCT03036124']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
586-594Subventions
Organisme : British Heart Foundation
ID : RE/18/6/34217
Pays : United Kingdom
Informations de copyright
© 2020 by the American Diabetes Association.